IPO Timeline
Broker Deadline
2026-05-08
Morning deadline
HKEX Deadline
2026-05-08
Noon deadline
Broker Results (T-2)
2026-05-11
Some brokers release in afternoon
Grey Market (T-1)
2026-05-12
Afternoon
HKEX Allotment (T-1)
2026-05-12
Evening
Registrar Allotment (T-1)
2026-05-12
Evening
Listing Day (T)
2026-05-13
First day of trading
Company Overview
| Stock Name | Jitai Technology |
|---|---|
| Stock Code | 07666 |
| Company Full Name | Jitai Technology |
| Industry | Biotech & Pharma |
| Principal Activities | important component of our integrated technology platform |
| Listing Date | 2026-05-13 |
| Listing Rules Era | New Rules (after Aug 2025) |
| Listing Rules Chapter | Chapter 18C |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | Daxing Biomedical Industry Base Zhongguancun Science Park Daxing District, Beijing, PRC Principal Place of Business in Room 1920, 19/F, Lee Garden One Hong Kong 33 Hysan Avenue, Causeway Bay, Hong Kon |
| Business Address (Hong Kong) | 香港銅鑼灣希慎道33號利苑一期19樓1920室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.metistechbio.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | Computershare Hong Kong Investor Services Limited |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Large IPO Exempt |
|---|---|
| Offer Price | HK$ 10.50 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 5,250 |
| Par Value | RMB 0.1 / shares |
| Offer Period | 2026-05-05 to 2026-05-08 |
| Global Offering Shares | 201,229,000 shares |
| HK Public Offer Shares (Initial) | 10,061,450 shares (5.0%) |
| Public Offer Lots (Initial) | 20,122lots (10,061lots, 10,061lots) |
| International Placing Shares (Initial) | 191,167,550 shares (95.0%) |
| Offer Ratio | ~17.46% |
| Total Shares Post-IPO | 1,152,513,850 shares |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 53.0% |
| Clawback Tiers | 回拨B档 |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 2,112,904,500 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 5,250 |
| 2 lots | 1,000 | HK$ 10,500 |
| 3 lots | 1,500 | HK$ 15,750 |
| 4 lots | 2,000 | HK$ 21,000 |
| 5 lots | 2,500 | HK$ 26,250 |
| 6 lots | 3,000 | HK$ 31,500 |
| 7 lots | 3,500 | HK$ 36,750 |
| 8 lots | 4,000 | HK$ 42,000 |
| 9 lots | 4,500 | HK$ 47,250 |
| 10 lots | 5,000 | HK$ 52,500 |
| 12 lots | 6,000 | HK$ 63,000 |
| 14 lots | 7,000 | HK$ 73,500 |
| 16 lots | 8,000 | HK$ 84,000 |
| 18 lots | 9,000 | HK$ 94,500 |
| 20 lots | 10,000 | HK$ 105,000 |
| 30 lots | 15,000 | HK$ 157,500 |
| 40 lots | 20,000 | HK$ 210,000 |
| 50 lots | 25,000 | HK$ 262,500 |
| 60 lots | 30,000 | HK$ 315,000 |
| 70 lots | 35,000 | HK$ 367,500 |
| 80 lots | 40,000 | HK$ 420,000 |
| 90 lots | 45,000 | HK$ 472,500 |
| 100 lots | 50,000 | HK$ 525,000 |
| 120 lots | 60,000 | HK$ 630,000 |
| 140 lots | 70,000 | HK$ 735,000 |
| 160 lots | 80,000 | HK$ 840,000 |
| 180 lots | 90,000 | HK$ 945,000 |
| 200 lots | 100,000 | HK$ 1,050,000 |
| 400 lots | 200,000 | HK$ 2,100,000 |
| 600 lots | 300,000 | HK$ 3,150,000 |
| 800 lots | 400,000 | HK$ 4,200,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,000 lots | 500,000 | HK$ 5,250,000 |
| 2,000 lots | 1,000,000 | HK$ 10,500,000 |
| 3,000 lots | 1,500,000 | HK$ 15,750,000 |
| 4,000 lots | 2,000,000 | HK$ 21,000,000 |
| 5,000 lots | 2,500,000 | HK$ 26,250,000 |
| 6,000 lots | 3,000,000 | HK$ 31,500,000 |
| 7,000 lots | 3,500,000 | HK$ 36,750,000 |
| 8,000 lots | 4,000,000 | HK$ 42,000,000 |
| 10,061 lots | 5,030,500 | HK$ 52,820,250 |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 12,101,395,425 |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | 不适用（公司处于亏损状态） |
| Profit/Loss Status | Net loss (see financial statements) |
| Period-End Cash Balance | 人民币561,500,000元 |
| Listing Expenses | ~HK$ 136,000,000 |
| Listing Expenses / Funds Raised | ~6.4% |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 23.8 |
|---|---|
| First Day Open | HK$ 28.68 |
| First Day Change | 126.67% |
| First Day Volume | 84545200.0 |
| First Day Turnover | 2403900000.0 |
Use of Proceeds
| Use of Proceeds | 1、約988.5百萬港元（約50.0%）將用于支撐公司的人工智能基礎設施及人工智能驅動納米材料平臺的核心技術研究、開發及推進； 2、約395.4百萬港元（約20.0%）將用于公司人工智能開發產品管線中正在進行及計劃開展的臨床試驗； 3、約197.7百萬港元（約10.0%）將用于開發公司的動物健康及抗衰解決方案，并將人工智能賦能的解決方案拓展至該等高增長領域； 4、約197.7百萬港元（約10.0%）將分配用于支持公司在全球構建人工智能驅動納米材料生態系統的增長戰略； 5、約197.7百萬港元（約10.0%）將用作營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
富瑞金融集团香港有限公司 CE ATS546
德意志证券亚洲有限公司 CE AAJ984
中信证券（香港）有限公司 CE AAK249
Sponsor cum Overall Coordinator (3)
富瑞金融集团香港有限公司 CE ATS546
德意志银行香港分行
中信里昂证券有限公司 CE AAB893
Overall Coordinators (4)
富瑞金融集团香港有限公司 CE ATS546
德意志银行香港分行
中信里昂证券有限公司 CE AAB893
招银国际融资有限公司 CE AVM940
Joint Global Coordinators (4)
富瑞金融集团香港有限公司 CE ATS546
德意志银行香港分行
中信里昂证券有限公司 CE AAB893
招银国际融资有限公司 CE AVM940
Joint Bookrunners (5)
富瑞金融集团香港有限公司 CE ATS546
德意志银行香港分行
中信里昂证券有限公司 CE AAB893
招银国际融资有限公司 CE AVM940
富途证券国际（香港）有限公司 CE AZT137
Joint Lead Managers (5)
富瑞金融集团香港有限公司 CE ATS546
德意志银行香港分行
中信里昂证券有限公司 CE AAB893
招银国际融资有限公司 CE AVM940
富途证券国际（香港）有限公司 CE AZT137
Capital Market Intermediaries (5)
富瑞金融集团香港有限公司 CE ATS546
德意志银行香港分行
中信里昂证券有限公司 CE AAB893
招银国际融资有限公司 CE AVM940
富途证券国际（香港）有限公司 CE AZT137
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
达维律师事务所 汉坤律师事务所 |
| Legal Advisor to Sponsors/Underwriters |
美迈斯律师事务所 通商律师事务所 |
| Auditor and Reporting Accountant | 罗兵咸永道会计师事务所 |
| Industry Advisor | 弗若斯特沙利文有限公司 |
| Compliance Advisor | 浤博资本有限公司 CE BPB716 |
| Receiving Banks | 招商永隆银行有限公司 |
| H Share Registrar | 香港中央证券登记有限公司 |
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 贝莱德 | 50,000,000 USD | 37,304,500 | 18.54% | 16.12% | 6 months | 2026-11-13 |
| 2 | UBS AM Singapore | 15,000,000 USD | 11,191,000 | 5.56% | 4.84% | 6 months | 2026-11-13 |
| 3 | 国风投创新投资基金股份有限公司 | 10,000,000 USD | 7,460,500 | 3.71% | 3.22% | 6 months | 2026-11-13 |
| 4 | 未来资产 | 8,000,000 USD | 5,968,500 | 2.97% | 2.58% | 6 months | 2026-11-13 |
| 5 | HHLRA | 8,000,000 USD | 5,968,500 | 2.97% | 2.58% | 6 months | 2026-11-13 |
| 6 | Deerfield | 5,000,000 USD | 3,730,000 | 1.85% | 1.61% | 6 months | 2026-11-13 |
| 7 | RTW基金 | 5,000,000 USD | 3,730,000 | 1.85% | 1.61% | 6 months | 2026-11-13 |
| 8 | Huadeng Technology | 5,000,000 USD | 3,730,000 | 1.85% | 1.61% | 6 months | 2026-11-13 |
| 9 | Isometry Global | 5,000,000 USD | 3,730,000 | 1.85% | 1.61% | 6 months | 2026-11-13 |
| 10 | 广发基金 | 5,000,000 USD | 3,730,000 | 1.85% | 1.61% | 6 months | 2026-11-13 |
| 11 | 工银瑞信实体 | 5,000,000 USD | 3,730,000 | 1.85% | 1.61% | 6 months | 2026-11-13 |
| 12 | 华夏基金（香港） | 5,000,000 USD | 3,730,000 | 1.85% | 1.61% | 6 months | 2026-11-13 |
| 13 | 富国基金 | 5,000,000 USD | 3,730,000 | 1.85% | 1.61% | 6 months | 2026-11-13 |
| 14 | Lake Bleu | 4,000,000 USD | 2,984,000 | 1.48% | 1.29% | 6 months | 2026-11-13 |
| 15 | Sage Partners | 4,000,000 USD | 2,984,000 | 1.48% | 1.29% | 6 months | 2026-11-13 |
| 16 | 工银理财 | 2,000,000 USD | 1,492,000 | 0.74% | 0.64% | 6 months | 2026-11-13 |
| 17 | ORIX Asia AM | 2,000,000 USD | 1,492,000 | 0.74% | 0.64% | 6 months | 2026-11-13 |
Directors & Management
| Chairman | Mr. Frank Yee Chon Lyn |
|---|---|
| Company Secretary | Dr. Chong Fu |
執行董事 (3)
| # | Name | English Name | Type |
|---|---|---|---|
| 1 | 赖才达 | — | 執行董事 |
| 2 | Hongming Chen | — | 執行董事 |
| 3 | 王文首 | — | 執行董事 |
非執行董事 (2)
| # | Name | English Name | Type |
|---|---|---|---|
| 1 | 黄瀚涛 | — | 非執行董事 |
| 2 | 公元 | — | 非執行董事 |
獨立非執行董事 (2)
| # | Name | English Name | Type |
|---|---|---|---|
| 1 | 林怡仲 | — | 獨立非執行董事 |
| 2 | 李晋 | — | 獨立非執行董事 |
Major Shareholders
| Major Shareholders & Holdings | substantial shareholder or any of his/its associates, our Company will comply with the applicable Listing Rules; (c) the independent non-executive Directors will review, on an annual basis, whether there is any conflict of interests between the Group and our Single Largest |
|---|
AI
AI Analysis
Market Sentiment
The IPO drew extreme enthusiasm with an oversubscription ratio of 6,910.96x, compressing the overall hit rate to just 17.15%. The Chapter 18C specialist tech status and biopharma sector appeal fueled overwhelming retail demand. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
At the A-tail (甲尾), applicants received a mere 0.1321 expected lots, while B-head (乙头) allocations reached 0.3638 lots—a 2.8x advantage. This wide gap shows that the top A-tier was heavily crowded, making B-head a notably more allocation-efficient tier in this distribution. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
Mainland China participation dominated at 58.9% of successful applicants, signaling strong cross-border appetite for a Chapter 18C biopharma listing. The investor base was 59.5% male, and the expanded holder count of 65,727 indicates broad retail distribution. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Offering Structure
Subscription Tiers
IPO Timeline
